Biomea Fusion Inc expected to post a loss of 22 cents a share - Earnings Preview
Biomea Fusion Inc expected to post a loss of 22 cents a share - Earnings Preview
Biomea Fusion Inc BMEA.OQ BMEA.O is expected to show no change in quarterly revenue when it reports results on August 3 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Biomea Fusion Inc is for a loss of 22 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.3% in the last three months.
Wall Street's median 12-month price target for Biomea Fusion Inc is $7.00, about 473.8% above its last closing price of $1.22
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.24 | -0.24 | -0.17 | Beat | 28.4 |
Dec. 31 2026 | -0.25 | 0.27 | Beat | 207.4 | |
Sep. 30 2025 | -0.25 | -0.26 | -0.27 | Missed | -5.5 |
Jun. 30 2025 | -0.53 | -0.53 | -0.51 | Beat | 3.9 |
Mar. 31 2025 | -0.60 | -0.61 | -0.80 | Missed | -30.8 |
Dec. 31 2024 | -0.92 | -0.81 | Beat | 12.1 | |
Sep. 30 2024 | -0.91 | -0.95 | -0.91 | Beat | 4.2 |
Jun. 30 2024 | -1.07 | -1.07 | -1.03 | Beat | 3.8 |
This summary was machine generated July 31 at 20:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes